FRANCE LAUNCH COMPASS · All indications · All regions · All facility types · All hub clusters · All institutions
Patient Pathways
Where are patients diagnosed, treated and referred?
All indications · All regions · All facility types · All hub clusters · All institutions
View referrals by
Median time to first treatment
MM28 dCLL77 d
Separate medians · MM n=32 · CLL n=18
Advanced-therapy referrals
1,473
ASCT 751 · CAR-T 321 · Bispecific step-up 401
Bone-marrow procedure proxy
10,835
Aspirates/yr at 15 institutions · per-patient averages below
Return-to-spoke rate
93%
20 corridors · 1,782 patients referred/yr
Bone-marrow sampling by patient profile
Transplant-eligible
2.3 aspirates / patient-year
20 contributing episodes
Transplant-ineligible
1.2 aspirates / patient-year
12 contributing episodes
Fixed-Duration CLL
0.9 aspirates / patient-year
12 contributing episodes
Continuous Oral BTKi CLL
0.4 aspirates / patient-year
6 contributing episodes
Treatment sequencing: first → second → third line
50 patient episodes · 12 distinct sequences
| Indication | First-line treatment | Second-line treatment | Third-line treatment | Episodes |
|---|---|---|---|---|
| MM | Dara-VRd + ASCT + Len Maint | Isa-Kd | Cilta-cel (Carvykti) | 5 |
| MM | Dara-VRd + ASCT + Len Maint | Second line not reached — in l1 remission | No third-line treatment recorded | 5 |
| MM | Isa-VRd + ASCT + Len Maint | Dara-Pd | Teclistamab (Tecvayli) | 5 |
| MM | VRd + ASCT + Len Maint | Dara-Kd | Ide-cel (Abecma) | 5 |
| CLL | Venetoclax + Obinutuzumab (12m) | Second line not reached — treatment-free remission | No third-line treatment recorded | 4 |
| CLL | Ibrutinib + Venetoclax (15m) | Second line not reached — treatment-free remission | No third-line treatment recorded | 4 |
Hub-and-spoke patient referrals
20 corridors
● Originating centre (including direct intake)■ Treating hubFlow width: annual patient volume
Patient-pathway explorer
Pseudonymised patient episodes
Centre
Patient profile
MRD status
50 of 50 records
| ANO-FR-2021001 | MM | M · 62 | Transplant-Eligible (TE) | 17 | Dara-VRd + ASCT + Len Maint | Isa-Kd | Cilta-cel (Carvykti) | ASCT | CAR-T (Cilta-cel) | 2.5 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021002 | MM | F · 52 | Transplant-Eligible (TE) | 37 | Dara-VRd + ASCT + Len Maint | Second line not reached — in l1 remission | No third-line treatment recorded | ASCT | None | 2 | NGS In-House (10^-6) | uMRD Negative (10^-6) | ||
| ANO-FR-2021003 | MM | M · 56 | Transplant-Eligible (TE) | 21 | Isa-VRd + ASCT + Len Maint | Dara-Pd | Teclistamab (Tecvayli) | ASCT | Bispecific (Teclistamab) | 2.2 | EuroFlow NGF (10^-5) | MRD Positive | ||
| ANO-FR-2021004 | MM | F · 55 | Transplant-Eligible (TE) | 18 | VRd + ASCT + Len Maint | Dara-Kd | Ide-cel (Abecma) | ASCT | CAR-T (Ide-cel) | 2.4 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021005 | MM | M · 79 | Transplant-Ineligible (TNE) | 17 | Dara-Rd (Continuous) | Isa-Pd | Talquetamab (Talvey) | No | Bispecific (Talquetamab) | 1.2 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021006 | MM | F · 78 | Transplant-Ineligible (TNE) | 37 | Dara-Rd (Continuous) | Second line not reached — in l1 | No third-line treatment recorded | No | None | 1 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021007 | MM | M · 82 | Transplant-Ineligible (TNE) | 31 | Dara-VMP | Carfilzomib-Dex (Kd) | Elranatamab (Elrexfio) | No | Bispecific (Elranatamab) | 1.5 | NGS Kit-Based (10^-6) | MRD Positive | ||
| ANO-FR-2021008 | MM | F · 53 | Transplant-Eligible (TE) | 32 | Dara-VRd + ASCT + Len Maint | Isa-Kd | Cilta-cel (Carvykti) | ASCT | CAR-T (Cilta-cel) | 2.5 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021009 | MM | M · 58 | Transplant-Eligible (TE) | 15 | Dara-VRd + ASCT + Len Maint | Second line not reached — in l1 remission | No third-line treatment recorded | ASCT | None | 2 | NGS In-House (10^-6) | uMRD Negative (10^-6) | ||
| ANO-FR-2021010 | MM | F · 52 | Transplant-Eligible (TE) | 16 | Isa-VRd + ASCT + Len Maint | Dara-Pd | Teclistamab (Tecvayli) | ASCT | Bispecific (Teclistamab) | 2.2 | EuroFlow NGF (10^-5) | MRD Positive | ||
| ANO-FR-2021011 | MM | M · 55 | Transplant-Eligible (TE) | 21 | VRd + ASCT + Len Maint | Dara-Kd | Ide-cel (Abecma) | ASCT | CAR-T (Ide-cel) | 2.4 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021012 | MM | F · 76 | Transplant-Ineligible (TNE) | 33 | Dara-Rd (Continuous) | Isa-Pd | Talquetamab (Talvey) | No | Bispecific (Talquetamab) | 1.2 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021013 | MM | M · 68 | Transplant-Ineligible (TNE) | 31 | Dara-Rd (Continuous) | Second line not reached — in l1 | No third-line treatment recorded | No | None | 1 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021014 | MM | F · 71 | Transplant-Ineligible (TNE) | 36 | Dara-VMP | Carfilzomib-Dex (Kd) | Elranatamab (Elrexfio) | No | Bispecific (Elranatamab) | 1.5 | NGS Kit-Based (10^-6) | MRD Positive | ||
| ANO-FR-2021015 | MM | M · 62 | Transplant-Eligible (TE) | 36 | Dara-VRd + ASCT + Len Maint | Isa-Kd | Cilta-cel (Carvykti) | ASCT | CAR-T (Cilta-cel) | 2.5 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021016 | MM | F · 60 | Transplant-Eligible (TE) | 27 | Dara-VRd + ASCT + Len Maint | Second line not reached — in l1 remission | No third-line treatment recorded | ASCT | None | 2 | NGS In-House (10^-6) | uMRD Negative (10^-6) | ||
| ANO-FR-2021017 | MM | M · 55 | Transplant-Eligible (TE) | 28 | Isa-VRd + ASCT + Len Maint | Dara-Pd | Teclistamab (Tecvayli) | ASCT | Bispecific (Teclistamab) | 2.2 | EuroFlow NGF (10^-5) | MRD Positive | ||
| ANO-FR-2021018 | MM | F · 61 | Transplant-Eligible (TE) | 22 | VRd + ASCT + Len Maint | Dara-Kd | Ide-cel (Abecma) | ASCT | CAR-T (Ide-cel) | 2.4 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021019 | MM | M · 80 | Transplant-Ineligible (TNE) | 41 | Dara-Rd (Continuous) | Isa-Pd | Talquetamab (Talvey) | No | Bispecific (Talquetamab) | 1.2 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021020 | MM | F · 68 | Transplant-Ineligible (TNE) | 38 | Dara-Rd (Continuous) | Second line not reached — in l1 | No third-line treatment recorded | No | None | 1 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021021 | MM | M · 80 | Transplant-Ineligible (TNE) | 19 | Dara-VMP | Carfilzomib-Dex (Kd) | Elranatamab (Elrexfio) | No | Bispecific (Elranatamab) | 1.5 | NGS Kit-Based (10^-6) | MRD Positive | ||
| ANO-FR-2021022 | MM | F · 63 | Transplant-Eligible (TE) | 27 | Dara-VRd + ASCT + Len Maint | Isa-Kd | Cilta-cel (Carvykti) | ASCT | CAR-T (Cilta-cel) | 2.5 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021023 | MM | M · 57 | Transplant-Eligible (TE) | 22 | Dara-VRd + ASCT + Len Maint | Second line not reached — in l1 remission | No third-line treatment recorded | ASCT | None | 2 | NGS In-House (10^-6) | uMRD Negative (10^-6) | ||
| ANO-FR-2021024 | MM | F · 54 | Transplant-Eligible (TE) | 20 | Isa-VRd + ASCT + Len Maint | Dara-Pd | Teclistamab (Tecvayli) | ASCT | Bispecific (Teclistamab) | 2.2 | EuroFlow NGF (10^-5) | MRD Positive | ||
| ANO-FR-2021025 | MM | M · 64 | Transplant-Eligible (TE) | 24 | VRd + ASCT + Len Maint | Dara-Kd | Ide-cel (Abecma) | ASCT | CAR-T (Ide-cel) | 2.4 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021026 | MM | F · 69 | Transplant-Ineligible (TNE) | 16 | Dara-Rd (Continuous) | Isa-Pd | Talquetamab (Talvey) | No | Bispecific (Talquetamab) | 1.2 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021027 | MM | M · 74 | Transplant-Ineligible (TNE) | 17 | Dara-Rd (Continuous) | Second line not reached — in l1 | No third-line treatment recorded | No | None | 1 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021028 | MM | F · 73 | Transplant-Ineligible (TNE) | 41 | Dara-VMP | Carfilzomib-Dex (Kd) | Elranatamab (Elrexfio) | No | Bispecific (Elranatamab) | 1.5 | NGS Kit-Based (10^-6) | MRD Positive | ||
| ANO-FR-2021029 | MM | M · 57 | Transplant-Eligible (TE) | 33 | Dara-VRd + ASCT + Len Maint | Isa-Kd | Cilta-cel (Carvykti) | ASCT | CAR-T (Cilta-cel) | 2.5 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021030 | MM | F · 56 | Transplant-Eligible (TE) | 39 | Dara-VRd + ASCT + Len Maint | Second line not reached — in l1 remission | No third-line treatment recorded | ASCT | None | 2 | NGS In-House (10^-6) | uMRD Negative (10^-6) | ||
| ANO-FR-2021031 | MM | M · 52 | Transplant-Eligible (TE) | 37 | Isa-VRd + ASCT + Len Maint | Dara-Pd | Teclistamab (Tecvayli) | ASCT | Bispecific (Teclistamab) | 2.2 | EuroFlow NGF (10^-5) | MRD Positive | ||
| ANO-FR-2021032 | MM | F · 59 | Transplant-Eligible (TE) | 31 | VRd + ASCT + Len Maint | Dara-Kd | Ide-cel (Abecma) | ASCT | CAR-T (Ide-cel) | 2.4 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021033 | CLL | M · 59 | Fixed-Duration CLL | 78 | Venetoclax + Obinutuzumab (12m) | Second line not reached — treatment-free remission | No third-line treatment recorded | No | None | 0.8 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021034 | CLL | F · 58 | Fixed-Duration CLL | 67 | Ibrutinib + Venetoclax (15m) | Second line not reached — treatment-free remission | No third-line treatment recorded | No | None | 1 | NGS In-House (10^-6) | uMRD Negative (10^-6) | ||
| ANO-FR-2021035 | CLL | M · 76 | Fixed-Duration CLL | 76 | Venetoclax + Obinutuzumab (12m) | Acalabrutinib (Continuous) | No third-line treatment recorded | No | None | 1 | ASO-qPCR (10^-4) | MRD Positive | ||
| ANO-FR-2021036 | CLL | F · 74 | Continuous Oral BTKi CLL | 376 | Acalabrutinib Monotherapy | Venetoclax + Rituximab (24m) | Pirtobrutinib | No | None | 0.5 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021037 | CLL | M · 78 | Continuous Oral BTKi CLL | 251 | Zanubrutinib Monotherapy | Second line not reached — on l1 btki | No third-line treatment recorded | No | None | 0.4 | Not Tested | Not Assessed | ||
| ANO-FR-2021038 | CLL | F · 57 | Fixed-Duration CLL | 59 | Venetoclax + Obinutuzumab (12m) | Second line not reached — treatment-free remission | No third-line treatment recorded | No | None | 0.8 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021039 | CLL | M · 65 | Fixed-Duration CLL | 40 | Ibrutinib + Venetoclax (15m) | Second line not reached — treatment-free remission | No third-line treatment recorded | No | None | 1 | NGS In-House (10^-6) | uMRD Negative (10^-6) | ||
| ANO-FR-2021040 | CLL | F · 63 | Fixed-Duration CLL | 42 | Venetoclax + Obinutuzumab (12m) | Acalabrutinib (Continuous) | No third-line treatment recorded | No | None | 1 | ASO-qPCR (10^-4) | MRD Positive | ||
| ANO-FR-2021041 | CLL | M · 68 | Continuous Oral BTKi CLL | 464 | Acalabrutinib Monotherapy | Venetoclax + Rituximab (24m) | Pirtobrutinib | No | None | 0.5 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021042 | CLL | F · 70 | Continuous Oral BTKi CLL | 553 | Zanubrutinib Monotherapy | Second line not reached — on l1 btki | No third-line treatment recorded | No | None | 0.4 | Not Tested | Not Assessed | ||
| ANO-FR-2021043 | CLL | M · 61 | Fixed-Duration CLL | 77 | Venetoclax + Obinutuzumab (12m) | Second line not reached — treatment-free remission | No third-line treatment recorded | No | None | 0.8 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021044 | CLL | F · 67 | Fixed-Duration CLL | 56 | Ibrutinib + Venetoclax (15m) | Second line not reached — treatment-free remission | No third-line treatment recorded | No | None | 1 | NGS In-House (10^-6) | uMRD Negative (10^-6) | ||
| ANO-FR-2021045 | CLL | M · 77 | Fixed-Duration CLL | 64 | Venetoclax + Obinutuzumab (12m) | Acalabrutinib (Continuous) | No third-line treatment recorded | No | None | 1 | ASO-qPCR (10^-4) | MRD Positive | ||
| ANO-FR-2021046 | CLL | F · 78 | Continuous Oral BTKi CLL | 253 | Acalabrutinib Monotherapy | Venetoclax + Rituximab (24m) | Pirtobrutinib | No | None | 0.5 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021047 | CLL | M · 75 | Continuous Oral BTKi CLL | 355 | Zanubrutinib Monotherapy | Second line not reached — on l1 btki | No third-line treatment recorded | No | None | 0.4 | Not Tested | Not Assessed | ||
| ANO-FR-2021048 | CLL | F · 73 | Fixed-Duration CLL | 61 | Venetoclax + Obinutuzumab (12m) | Second line not reached — treatment-free remission | No third-line treatment recorded | No | None | 0.8 | EuroFlow NGF (10^-5) | uMRD Negative (10^-5) | ||
| ANO-FR-2021049 | CLL | M · 61 | Fixed-Duration CLL | 89 | Ibrutinib + Venetoclax (15m) | Second line not reached — treatment-free remission | No third-line treatment recorded | No | None | 1 | NGS In-House (10^-6) | uMRD Negative (10^-6) | ||
| ANO-FR-2021050 | CLL | F · 68 | Fixed-Duration CLL | 64 | Venetoclax + Obinutuzumab (12m) | Acalabrutinib (Continuous) | No third-line treatment recorded | No | None | 1 | ASO-qPCR (10^-4) | MRD Positive |